Year All202420232022202120202019201820172016201520142013201220112009 Feb 27, 2024 REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights Feb 21, 2024 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights Feb 07, 2024 REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint Feb 07, 2024 REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial Jan 31, 2024 REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 Jan 16, 2024 REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Jan 10, 2024 REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
Feb 27, 2024 REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Feb 21, 2024 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Feb 07, 2024 REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
Feb 07, 2024 REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Jan 16, 2024 REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery